AbCellera Biologics Inc.
ABCL· Nasdaq
Released Nov 6, 2025, after the close
10-Q filed Nov 6, 2025, 37 days after period end · 0001703057-25-000025
| Metric | Q3 2025 | Q3 2024 | Q3 2023 | Q3 2022 |
|---|---|---|---|---|
| Revenue | $8.96M | $6.51M | $6.60M | $101.38M |
| Net Income | -$57.12M | -$51.11M | -$28.61M | $26.62M |
| EPS Diluted |
AbCellera Biologics Inc. · CIK 1703057 · Engraved from SEC EDGAR
| -$0.19 |
| -$0.17 |
| -$0.10 |
| $0.08 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.